SETD2 and endometrial carcinoma: This finding was a confirmation of preclinical data and identify a distinct role of SETD2 between endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma and bladder urinary cancer, renal carcinoma, NSCLC, melanoma.